Wexford Capital’s Seres Therapeutics MCRB Stock Holding History

Wexford Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,022	Closed	-$28.6K	–	261
2023 Q4	$28.6K	Buy	+1,022	New	+$26.8K	0.01%	163

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Wexford Capital's MCRB Position: Q1 2024 in Review

Wexford Capital sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 1,022 shares — an estimated $28.6K sold.

Wexford Capital first reported a position in MCRB in Q4 2023 and held it in 1 quarter. The position peaked at $28.6K in Q4 2023. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

Wexford Capital reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 1,022 Seres Therapeutics shares in Q1 2024, an estimated $28.6K.
Wexford Capital first reported a position in Seres Therapeutics in Q4 2023 and held it in 1 quarter.
Wexford Capital's Seres Therapeutics position peaked at $28.6K in Q4 2023.
99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.